Cogent Biosciences, Inc.

This study tests a new drug called CGT9486 (bezuclastinib) in people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug aims to control the disease by targeting a specific genetic mutation. About 140 adults with aggressive forms of the condition will…

This program provides early access to an investigational drug called bezuclastinib, taken together with sunitinib, for people with advanced gastrointestinal stromal tumors (GIST) who have no other good treatment choices. The combination targets many types of KIT mutations that dr…

This program offers bezuclastinib, an investigational drug, to adults with systemic mastocytosis who have tried and failed at least one approved therapy or have no other good options. The goal is to provide disease control when standard treatments are not working. Participants mu…

This early-phase study tests a new oral drug, CGT4255, in about 100 adults whose advanced solid tumors have certain genetic changes (ERBB2 alterations or HER2 overexpression). The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors, includi…